TY  - JOUR
AU  - Christiansen, D
AU  - Earnest-Silveira, L
AU  - Chua, B
AU  - Meuleman, P
AU  - Boo, I
AU  - Grubor-Bauk, B
AU  - Jackson, DC
AU  - Keck, ZY
AU  - Foung, SKH
AU  - Drummer, HE
AU  - Gowans, EJ
AU  - Torresi, J
Y2  - 2020/12/17
Y1  - 2018/04/24
SN  - 2045-2322
UR  - http://hdl.handle.net/11343/254880
AB  - The significant public health problem of Hepatitis C virus (HCV) has been partially addressed with the advent of directly acting antiviral agents (DAAs). However, the development of an effective preventative vaccine would have a significant impact on HCV incidence and would represent a major advance towards controlling and possibly eradicating HCV globally. We previously reported a genotype 1a HCV viral-like particle (VLP) vaccine that produced neutralizing antibodies (NAb) and T cell responses to HCV. To advance this approach, we produced a quadrivalent genotype 1a/1b/2a/3a HCV VLP vaccine to produce broader immune responses. We show that this quadrivalent vaccine produces antibody and NAb responses together with strong T and B cell responses in vaccinated mice. Moreover, selective neutralizing human monoclonal antibodies (HuMAbs) targeting conserved antigenic domain B and D epitopes of the E2 protein bound strongly to the HCV VLPs, suggesting that these critical epitopes are expressed on the surface of the particles. Our findings demonstrate that a quadrivalent HCV VLP based vaccine induces broad humoral and cellular immune responses that will be necessary for protection against HCV. Such a vaccine could provide a substantial addition to highly active antiviral drugs in eliminating HCV.
LA  - English
PB  - NATURE PUBLISHING GROUP
T1  - Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine
DO  - 10.1038/s41598-018-24762-9
IS  - Scientific Reports
VL  - 8
IS  - 1
OP  - 1060436
OP  - 1126379
L1  - /bitstream/handle/11343/254880/PMC5915487.pdf?sequence=1&isAllowed=y
ER  -